Eli Lilly & Company have announced that Laura Steele has been appointed President and General Manager (GM) for UK, Ireland & Northern Europe.
Laura succeeds Ashley Diaz-Granados, who assumes a senior role within Lilly USA leading the company’s Immunology division. Laura will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience.
Laura brings 18 years’ experience with the company to her new role, and joins from Lilly’s Corporate Business Development division, where she specialised in innovation partnerships, large-scale projects in M&A, investments and joint ventures, to drive growth across the company.
A statement from Lilly UK maintained that, since the start of her career, Laura has built a reputation for driving innovation and patient-centricity and is a global champion of diversity and inclusion within the company, passionate about overcoming inequalities and building high-performing teams. Under Laura’s leadership, Lilly will continue to work to deliver innovative medicines to patients in Northern Europe with the ambition to launch at least 20 medicines in the 10 years from 2014 to 2023.
Commenting on her new role, Laura Steele said: “I am honoured to take on this role at such defining moment for the Life Sciences industry in the UK. The new Life Sciences Vision illustrates how all aspects of the health system must work together to ensure we can continue to discover and deliver new life-saving innovations here in the UK. Lilly, as well as the wider industry, are well placed to help drive this forward. As we emerge from the COVID-19 pandemic, we must build on what we have learned during this crisis. From accelerating the set-up of new clinical trials to advances in delivering care outside of traditional settings, and combating health inequalities, the partnership and advances in care created during the pandemic must not be lost.”